A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Pharmacokinetics of DUR-928 in Healthy Volunteers Following Daily Oral Dosing
Latest Information Update: 02 Jul 2019
At a glance
- Drugs Larsucosterol (Primary)
- Indications Fatty liver
- Focus Pharmacokinetics
- Sponsors INC Research
- 16 Jul 2015 Status changed from recruiting to completed as per Australian New Zealand Clinical Trials Registry record.
- 18 Jun 2015 Planned number of patients changed from 20 to 28 as per Australian New Zealand Clinical Trials Registry.
- 18 Jun 2015 Status changed from active, no longer recruiting to recruiting as per Australian New Zealand Clinical Trials Registry.